New combo therapy targets aggressive lung cancer transformation
NCT ID NCT06830694
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a combination of tarlatamab (a targeted immune therapy), chemotherapy, and atezolizumab in 50 adults whose lung cancer has transformed from a common type (adenocarcinoma) to a more aggressive small cell form after initial treatment. The goal is to see if this approach can improve how long people live without their cancer growing. Participants must have a specific EGFR mutation and no prior treatment for the transformed cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tarlatamab (a drug that helps immune cells attack cancer), combined with chemotherapy (etoposide, carboplatin) and immunotherapy (atezolizumab)
What this could lead to
If successful, this could offer a new, more effective treatment option for people whose lung cancer has transformed into a hard-to-treat type after initial therapy.
What could go wrong
This is a small, early-phase trial (50 people) with no control group, so results may not apply broadly. The combination also carries risks of serious side effects from chemotherapy and immune-related reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL CARCINOMA OF LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Samsung Medical Center
RECRUITINGSeoul, Gangnam-gu, 06351, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••